Actelion, Genentech co-promote tezosentan in US
Actelion, a biotech company specializing in therapeutics for diseases involving the vascular endothelium, will co-promote tezosentan in the US with Genentech; Actelion originally licensed the drug from Hoffmann-La Roche in 1998.
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com